Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2010

01-08-2010 | Bone and Soft Tissue Sarcomas

Dermatofibrosarcoma Protuberans: How Wide Should We Resect?

Authors: Jeffrey M. Farma, MD, John B. Ammori, MD, Jonathan S. Zager, MD, Suroosh S. Marzban, BS, Marilyn M. Bui, MD, PhD, Christopher K. Bichakjian, MD, Timothy M. Johnson, MD, Lori Lowe, MD, Michael S. Sabel, MD, Sandra L. Wong, MD, G. Douglas Letson, MD, Jane L. Messina, MD, Vincent M. Cimmino, MD, Vernon K. Sondak, MD

Published in: Annals of Surgical Oncology | Issue 8/2010

Login to get access

Abstract

Background

Dermatofibrosarcoma protuberans (DFSP) is a rare dermal tumor with local recurrence rates ranging from 0 to 50%. Controversy exists regarding margin width and excision techniques, with some advocating Mohs surgery and others wide excision (WE). We reviewed the experience in two tertiary centers using WE with total peripheral margin pathologic evaluation.

Materials and Methods

Institutional Review Board approved retrospective review of patients with DFSP from 1991 to 2008. Patients had initial WE using 1–2 cm margins with primary or delayed closure; further excision was done whenever feasible for positive margins. Pathologic analysis included en face sectioning. We evaluated margin width, number of WE, reconstruction methods, radiation, and outcomes.

Results

A total of 206 DFSP lesions in 204 patients (76 males, 128 females), median age 41 years (range 1–84) were treated. Locations were trunk (135), extremities (43), and head and neck (28). The median number of excisions to achieve negative margins was 1 (range 1–4) with a median excision width of 2 cm (range 0.5–3 cm). Closure techniques included primary closure (142; 69%), skin grafting (52; 25%), and tissue flaps (9; 4%). There were 9 patients who received postoperative radiation, 6 for positive margins after maximal surgical excision. At a median follow-up of 64 months (range 1–210), 2 patients (1%) with head and neck primaries recurred locally.

Conclusions

Using a standardized surgical approach including meticulous pathologic evaluation of margins, a very low recurrence rate (1%) was achieved with relatively narrow margins (median 2 cm), allowing primary closure in 69% of patients. This approach spares the additional morbidity associated with wider resection margins and in our experience represents the treatment of choice for DFSP occurring on the trunk and extremities.
Literature
1.
2.
Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113:616–27.CrossRefPubMed
3.
Taylor HB, Helwig EB. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer. 1962;15:717–25.CrossRefPubMed
4.
Monnier D, Vidal C, Martin L, Danzon A, Pelletier F, Puzenat E, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol. 2006;20:1237–42.CrossRefPubMed
5.
DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008–16.CrossRefPubMed
6.
Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, et al. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711–20.CrossRefPubMed
7.
Yu W, Tsoukas MM, Chapman SM, Rosen JM. Surgical treatment for dermatofibrosarcoma protuberans: the Dartmouth experience and literature review. Ann Plast Surg. 2008;60:288–93.CrossRefPubMed
8.
Hancox JG, Kelley B, Greenway HT, Jr. Treatment of dermatofibroma sarcoma protuberans using modified Mohs micrographic surgery: no recurrences and smaller defects. Dermatol Surg. 2008;34:780–4.CrossRefPubMed
9.
Paradisi A, Abeni D, Rusciani A, Cigna E, Wolter M, Scuderi N, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev. 2008;34:728–36.CrossRefPubMed
10.
Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer. 2004;101:28–38.CrossRefPubMed
11.
Nouri K, Lodha R, Jimenez G, Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg. 2002;28:1060–4; discussion 1064.CrossRefPubMed
12.
Nelson RA, Arlette JP. Mohs micrographic surgery and dermatofibrosarcoma protuberans: a multidisciplinary approach in 44 patients. Ann Plast Surg. 2008;60:667–72.CrossRefPubMed
13.
Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600–13.CrossRefPubMed
14.
Kimmel Z, Ratner D, Kim JY, Wayne JD, Rademaker AW, Alam M. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol. 2007;14:2113–20.CrossRefPubMed
15.
Stojadinovic A, Karpoff HM, Antonescu CR, Shah JP, Singh B, Spiro RH, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol. 2000;7:696–704.CrossRefPubMed
16.
Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341–5.PubMed
17.
Heuvel ST, Suurmeijer A, Pras E, Van Ginkel RJ, Hoekstra HJ. Dermatofibrosarcoma protuberans: Recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol. 2009;36:89–94.PubMed
18.
Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669–75.CrossRefPubMed
19.
Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall W. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol. 2005;28:537–9.CrossRefPubMed
20.
Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet. 2003;140:1–12.CrossRefPubMed
21.
Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95–8.CrossRefPubMed
22.
Handolias D, McArthur GA. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. Future Oncol. 2008;4:211–7.CrossRefPubMed
23.
McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–73.CrossRefPubMed
24.
Meguerditchian AN, Wang J, Lema B, Kraybill WG, Zeitouni NC, Kane JM 3rd. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol. 2009 [Epub ahead of print].
Metadata
Title
Dermatofibrosarcoma Protuberans: How Wide Should We Resect?
Authors
Jeffrey M. Farma, MD
John B. Ammori, MD
Jonathan S. Zager, MD
Suroosh S. Marzban, BS
Marilyn M. Bui, MD, PhD
Christopher K. Bichakjian, MD
Timothy M. Johnson, MD
Lori Lowe, MD
Michael S. Sabel, MD
Sandra L. Wong, MD
G. Douglas Letson, MD
Jane L. Messina, MD
Vincent M. Cimmino, MD
Vernon K. Sondak, MD
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1046-8

Other articles of this Issue 8/2010

Annals of Surgical Oncology 8/2010 Go to the issue

Hepatobiliary Tumors

Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization

Colorectal Cancer

Preoperative Staging with Chest CT in Patients with Colorectal Carcinoma: Not as a Routine Procedure

Colorectal Cancer

Stromal CXCR4 and CXCL12 Expression is Associated with Distant Recurrence and Poor Prognosis in Rectal Cancer After Chemoradiotherapy

Gastrointestinal Oncology

Histological Regression of Squamous Esophageal Carcinoma Assessed by Percentage of Residual Viable Cells after Neoadjuvant Chemoradiation is an Important Prognostic Factor

Translational Research and Biomarkers

Clinical Implication and Mitotic Effect of CD44 Cleavage in Relation to Osteopontin/CD44 Interaction and Dysregulated Cell Cycle Protein in Gastrointestinal Stromal Tumor

Melanomas

Creating and Providing Predictions of Melanoma Outcome